A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity

Drug pH-Sensitive Release in Vitro and Targeting Ability of Polyamidoamine Dendrimer Complexes for Tumor Cells

(2011) Dan Liu et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Polyaspartamide-graft-Polymethacrylate Nanoparticles for Doxorubicin Delivery

(2011) Mariano Licciardi et al.   MACROMOLECULAR BIOSCIENCE

New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers

(2010) Konstantinos Gardikis et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer

(2010) Yunching Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug

(2010) Ashay Jain et al.   JOURNAL OF CONTROLLED RELEASE

New Drug Delivery Nanosystem Combining Liposomal and Dendrimeric Technology (Liposomal Locked-In Dendrimers) for Cancer Therapy

(2010) Konstantinos Gardikis et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Flexible Filaments forin VivoImaging and Delivery: Persistent Circulation of Filomicelles Opens the Dosage Window for Sustained Tumor Shrinkage

(2009) David A. Christian et al.   MOLECULAR PHARMACEUTICS

Accelerated Blood Clearance Phenomenon Upon Repeated Injection of PEG-modified PLA-nanoparticles

(2009) Tsutomu Ishihara et al.   PHARMACEUTICAL RESEARCH

Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts

(2008) Roger von Moos et al.   EUROPEAN JOURNAL OF CANCER

In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells

(2008) Ken-ichi Ogawara et al.   JOURNAL OF CONTROLLED RELEASE

Preparation and characterization of HA–PEG–PCL intelligent core–corona nanoparticles for delivery of doxorubicin

(2008) Awesh Kumar Yadav et al.   JOURNAL OF DRUG TARGETING

Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process

(2008) I. Hamad et al.   MOLECULAR IMMUNOLOGY